Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Johnson and Johnson
Daiichi Sankyo
Boehringer Ingelheim

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,618,649

« Back to Dashboard

Which drugs does patent 7,618,649 protect, and when does it expire?

Patent 7,618,649 protects CLARINEX D 24 HOUR, CLARINEX-D 12 HOUR, and CLARINEX, and is included in three NDAs. There have been two Paragraph IV challenges on Clarinex.

Protection for CLARINEX D 24 HOUR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,618,649

Title:Extended release oral dosage composition
Abstract:A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
Inventor(s): Cho; Wing-Kee Philip (Princeton, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:10/699,987
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp DohmeCLARINEX D 24 HOURdesloratadine; pseudoephedrine sulfateTABLET, EXTENDED RELEASE;ORAL021605-001Mar 3, 2005ABRXYesYes► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeCLARINEX-D 12 HOURdesloratadine; pseudoephedrine sulfateTABLET, EXTENDED RELEASE;ORAL021313-001Feb 1, 2006RXYesYes► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeCLARINEXdesloratadineTABLET, ORALLY DISINTEGRATING;ORAL021312-002Jul 14, 2005ABRXYesNo► Subscribe► SubscribeY► Subscribe
Merck Sharp DohmeCLARINEXdesloratadineTABLET, ORALLY DISINTEGRATING;ORAL021312-001Jun 26, 2002ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: